Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Harvard Business School
AstraZeneca
Dow
Moodys
Medtronic
Boehringer Ingelheim

Last Updated: November 11, 2019

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 204569

See Plans and Pricing

« Back to Dashboard

NDA 204569 describes BELSOMRA, which is a drug marketed by Merck Sharp Dohme and is included in one NDA. It is available from one supplier. There are two patents protecting this drug. Additional details are available on the BELSOMRA profile page.

The generic ingredient in BELSOMRA is suvorexant. One supplier is listed for this compound. Additional details are available on the suvorexant profile page.
Summary for 204569
Tradename:BELSOMRA
Applicant:Merck Sharp Dohme
Ingredient:suvorexant
Patents:2
Generic Entry Opportunity Date for 204569
Generic Entry Date for 204569*:
Constraining patent/regulatory exclusivity:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Suppliers and Packaging for NDA: 204569
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
BELSOMRA suvorexant TABLET;ORAL 204569 NDA Merck Sharp & Dohme Corp. 0006-0005 0006-0005-13 1 BLISTER PACK in 1 CASE (0006-0005-13) > 3 TABLET, FILM COATED in 1 BLISTER PACK
BELSOMRA suvorexant TABLET;ORAL 204569 NDA Merck Sharp & Dohme Corp. 0006-0005 0006-0005-30 3 CASE in 1 CARTON (0006-0005-30) > 1 BLISTER PACK in 1 CASE (0006-0005-10) > 10 TABLET, FILM COATED in 1 BLISTER PACK

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength5MG
Approval Date:Aug 13, 2014TE:RLD:Yes
Regulatory Exclusivity Expiration:Aug 13, 2019
Regulatory Exclusivity Use:NEW CHEMICAL ENTITY
Patent:  Start TrialPatent Expiration:May 29, 2033Product Flag?YSubstance Flag?Delist Request?
Patent:  Start TrialPatent Expiration:Nov 20, 2029Product Flag?YSubstance Flag?YDelist Request?
Patented Use:TREATMENT OF INSOMNIA

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Moodys
Colorcon
Johnson and Johnson
Mallinckrodt
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.